专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012011778A3 CANCER DIAGNOSIS KIT AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER 审中-公开
标题翻译：癌症诊断试剂盒和药物组合物预防或治疗癌症
公开(公告)号：WO2012011778A3
公开(公告)日：2012-05-24
申请号：PCT/KR2011005433
申请日：2011-07-22
申请人： KOREA RES INST OF BIOSCIENCE , CHUNG KYUNG SOOK , WON MI SUN , AHN JI WON , KIM YOUNG JOO , SONG EUN YOUNG , YEOM YOUNG IL , LEE HEE GU
发明人： CHUNG KYUNG SOOK , WON MI SUN , AHN JI WON , KIM YOUNG JOO , SONG EUN YOUNG , YEOM YOUNG IL , LEE HEE GU
IPC分类号： C12Q1/68 , A61K48/00 , C12N15/12 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to a composition for cancer diagnosis having a formulation for measuring the expression level of Chromosome 10 open reading frame 81 (C10orf81) gene mRNA or protein thereof, a kit for cancer diagnosis having the composition, a method for providing information on cancer diagnosis including a step for measuring the expression level of C10orf81 gene mRNA or the expression level of protein coded by the gene, and a method for screening pharmaceutical compositions for the prevention or the treatment of cancer including an expression inhibitor for the C10orf81 gene or an activity inhibitor for the protein thereof, and therapeutic agents for cancer. The present invention enables an accurate diagnosis of cancer by providing genes specific to stomach cancer, liver cancer, colorectal cancer, lung cancer, or prostate cancer, and diagnostic markers for determining the metastasis and prognosis of the cancer, and can be useful in the diagnosis and prognosis management of cancer. Also, the present invention enables the development of new bio-medicines having fewer side effects and customized anticancer drugs by providing a cancer-specific therapeutic agent capable of inhibiting the gene.
摘要翻译：本发明涉及用于癌症诊断的组合物，其具有用于测量染色体10开放阅读框81（C10orf81）基因mRNA或其蛋白质的表达水平的制剂，具有该组成的癌症诊断用试剂盒，提供癌症信息的方法诊断包括测量C10orf81基因mRNA的表达水平的步骤或由该基因编码的蛋白质的表达水平的步骤，以及用于筛选用于预防或治疗癌症的药物组合物的方法，包括用于C10orf81基因的表达抑制剂或活性其蛋白质的抑制剂和癌症治疗剂。本发明能够通过提供对胃癌，肝癌，结肠直肠癌，肺癌或前列腺癌特异性的基因和用于确定癌症的转移和预后的诊断标记物来准确诊断癌症，并且可用于诊断和癌症的预后管理。此外，通过提供能够抑制该基因的癌症特异性治疗剂，本发明能够开发副作用较少的新生物药物和定制的抗癌药物。

2. 发明申请

WO2012023802A3 METHOD AND APPARATUS FOR LOCATING A SOURCE OF DAMAGE IN A LARGE COMPOSITE MATERIAL STRUCTURE 审中-公开
标题翻译：用于在大型复合材料结构中定位损伤源的方法和设备
公开(公告)号：WO2012023802A3
公开(公告)日：2012-05-03
申请号：PCT/KR2011006045
申请日：2011-08-17
申请人： KOREA RES INST OF STANDARDS , YOON DONG JIN , HAN BYEONG HEE , KIM YOUNG JOO
发明人： YOON DONG JIN , HAN BYEONG HEE , KIM YOUNG JOO
IPC分类号： G01N29/04 , G01N29/14
CPC分类号： G01N29/44 , G01N29/069 , G01N29/14 , G01N29/42 , G01N2291/0231 , G01N2291/2693
摘要： The present invention relates to a method for locating a source of damage in a blade of a wind power generator, capable of tracing the source of damage in a blade used in a wind power generator. More particularly, the present invention relates to a method and apparatus for locating a source of damage in a blade of a wind power generator, which involve detecting defects using an attenuation map prepared on the basis of energy values of elastic waves so as to accurately locate a source of damage in a large composite material structure. The method for locating a source of damage in a blade of a wind power generator according to the present invention enables a source of damage in a large composite material structure made of two or more materials to be accurately located in a different manner than conventional techniques, and fewer AE sensors to be used as compared to conventional techniques.
摘要翻译：本发明涉及一种用于定位风力发电机的叶片中的损坏源的方法，该方法能够追踪风力发电机中使用的叶片中的损伤源。更具体地说，本发明涉及一种用于定位风力发电机的叶片中的损伤源的方法和设备，该方法和设备涉及使用基于弹性波的能量值准备的衰减图来检测缺陷，以便精确定位这是大型复合材料结构中的一种损伤源。根据本发明的用于定位风力发电机的叶片中的损坏源的方法使得能够以与常规技术不同的方式精确定位由两种或更多种材料制成的大型复合材料结构中的损伤源，与传统技术相比，使用更少的AE传感器。

3. 发明申请

WO2010067984A2 NOVEL BIOMARKER FOR LIVER CANCER AND APPLICATIONS FOR SAME 审中-公开
标题翻译：新的肝癌生物标志物及其应用
公开(公告)号：WO2010067984A2
公开(公告)日：2010-06-17
申请号：PCT/KR2009007202
申请日：2009-12-03
申请人： KOREA RES INST OF BIOSCIENCE , SONG EUN YOUNG , LEE HEE GU , YEOM YOUNG IL , JI NA YOUNG , LEE JUNG IL , KANG MIN A , KIM YOUNG JOO , KANG YOON HEE , KIM JAE WHA
发明人： SONG EUN YOUNG , LEE HEE GU , YEOM YOUNG IL , JI NA YOUNG , LEE JUNG IL , KANG MIN A , KIM YOUNG JOO , KANG YOON HEE , KIM JAE WHA
IPC分类号： C12Q1/68 , C12N15/12 , G01N33/574
CPC分类号： C07K14/4748 , C12Q1/6886 , C12Q2600/158 , G01N33/57438 , G01N2800/50
摘要： The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer. The markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer.
摘要翻译：本发明涉及可用作肝癌诊断的新型标志物的基因的阐明以及使用其的肝癌的诊断和预后测量。更具体而言，涉及一种诊断试剂盒，其能够使用测定选自由S100P，NK4，CCL20，CSPG2等组成的肝癌诊断标志物组中的至少一个基因的表达量的制剂，进行肝癌的诊断和预后测定。 PLA12，MMP12，ESM-1，ABHD7，HCAPG，CXCL-3，Col5A2，MAGEA，GSN，CDC2，CST1，MELK，ATAD2，FAP和MSN和/或使用其诊断和预测肝癌的方法。已经发现使用从本发明的相同肝癌患者采集的正常肝组织和肝癌组织，并且代表了其准确性和可靠性作为肝癌标志物已经大大提高的标志物。本发明的标记物可用于肝癌的准确诊断和预后。

4. 发明申请

WO2007120008A1 EXTRACT OF CHRYSANTHEMUM ZAWADSKII REMOVING HANGOVER ACTIVITY 审中-公开
标题翻译：提取枸杞子除草活性
公开(公告)号：WO2007120008A1
公开(公告)日：2007-10-25
申请号：PCT/KR2007/001869
申请日：2007-04-17
申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , YANG, Hyun Ok , YOO, Ji-Hye , KIM, Young-Joo , KIM, Su-Jeong , SUH, Jong-Teak , JUNG, Sang Hoon , CHA, Kwang-Hyun , KIM, Su-Nam , NHO, Chu Won , LEE, Saet Byoul , MOON, Kil Choo
发明人： YANG, Hyun Ok , YOO, Ji-Hye , KIM, Young-Joo , KIM, Su-Jeong , SUH, Jong-Teak , JUNG, Sang Hoon , CHA, Kwang-Hyun , KIM, Su-Nam , NHO, Chu Won , LEE, Saet Byoul , MOON, Kil Choo
IPC分类号： A61K36/287
CPC分类号： A61K36/287
摘要： The present invention relates to use of the extract of Chrysanthemum zawadskii that is extracted using water, alcohol or a mixture thereof. Particularly, the extract of Chrysanthemum zawadskii can be used for an ant i- hangover agent because it can reduce alcohol density and acetaldehyde density in blood by promoting in vivo alcohol metabolism through improving activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), and present radical removal ability. The extract of Chrysanthemum zawadskii of the present invention can be used as an anti -hangover agent and health food for removing hangover because it can get rid of hangover more efficiently than hangover removing beverages in the market.
摘要翻译：本发明涉及使用水，醇或其混合物提取菊苣提取物的用途。特别地，菊花提取物可用于蚂蚁中毒剂，因为它可以通过改善醇脱氢酶（ADH）和乙醛脱氢酶（ALDH）的活性来促进体内酒精代谢，从而降低血液中的酒精密度和乙醛密度，并具有根本的清除能力。本发明的菊花提取物可以用作抗脱水剂和用于去除宿醉的保健食品，因为它可以比在市场上去除饮料的宿醉更有效地摆脱宿醉。

5. 发明申请

WO2007108621A1 SIRNA FOR INHIBITING NF-KB/RELA EXPRESSION 审中-公开
标题翻译： SIRNA抑制NF-KB / RELA表达
公开(公告)号：WO2007108621A1
公开(公告)日：2007-09-27
申请号：PCT/KR2007/001319
申请日：2007-03-17
申请人： BIONEER CORPORATION , CHOI, Young Chul , PARK, Han Oh , CHOUNG, So Rim , KIM, Seon Hoe , KIM, Ji Young , LEE, Eun Ju , LEE, Mi Young , KIM, Young Joo , LEE, Ui Jin , HAN, Chang Whan
发明人： CHOI, Young Chul , PARK, Han Oh , CHOUNG, So Rim , KIM, Seon Hoe , KIM, Ji Young , LEE, Eun Ju , LEE, Mi Young , KIM, Young Joo , LEE, Ui Jin , HAN, Chang Whan
IPC分类号： C12N15/11 , A61K48/00
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3521
摘要： The present invention relates to siRNA for inhibiting NF-κB/RelA and a pharmaceutical composition for treating rheumatoid arthritis. The pharmaceutical composition for treating rheumatoid arthritis of present invention comprises an active ingredient of siRNA which binds with mRNA transcribed from a gene coding for NF-κB/RelA to inhibit NF-κB/RelA expression in a cell. The pharmaceutical composition for treating rheumatoid arthritis can directly inhibit NF-κB/RelA expression in the gene level as well as induce the death of abnormally proliferated synovial cells, which makes possible its practical application for the treatment of rheumatoid arthritis in a more efficient manner.
摘要翻译：本发明涉及用于抑制NF-κB/ RelA的siRNA和用于治疗类风湿性关节炎的药物组合物。用于治疗本发明类风湿性关节炎的药物组合物包含与编码NF-κB/ RelA的基因转录的mRNA结合以抑制细胞中NF-κB/ RelA表达的siRNA活性成分。用于治疗类风湿性关节炎的药物组合物可以直接抑制基因水平的NF-κB/ RelA表达，并诱导异常增殖的滑膜细胞死亡，这使其成为可能以更有效的方式治疗类风湿性关节炎的实际应用。

6. 发明申请

WO2012124903A3 DUMP-TYPE TRANSPORT CONTAINER HAVING LOCKING DEVICE 审中-公开
标题翻译：具有锁定装置的倾卸式运输集装箱
公开(公告)号：WO2012124903A3
公开(公告)日：2012-12-27
申请号：PCT/KR2012001213
申请日：2012-02-17
申请人： KOREA RAILROAD RES INST , KWON YONG JANG , KIM KYOUNG TAE , LEE SUK , KIM YOUNG JOO
发明人： KWON YONG JANG , KIM KYOUNG TAE , LEE SUK , KIM YOUNG JOO
IPC分类号： B65D88/12 , B60P1/64
CPC分类号： B65D88/123 , B60P1/26 , B65D90/623
摘要： The present invention relates to a dump-type transport container having a locking device, and more particularly, to a transport container having a locking device for preventing a door from opening and spilling loaded items when moving while carrying the loaded items in the dump-type transport container. The accommodation container of the present invention comprises: a container body for accommodating the loaded items, and which has a open top surface; a door formed on the rear surface of the container body so as to allow opening/closing thereof; and a locking portion for locking or unlocking the door from both side surfaces of the door.
摘要翻译：具有锁定装置的倾卸式运输容器技术领域本发明涉及一种具有锁定装置的倾卸式运输容器，并且更具体地涉及一种具有锁定装置的运输容器，所述锁定装置用于防止门在运输时将门上的物品打开和溢出，运输集装箱。本发明的容纳容器包括：用于容纳装载物品的容器主体，并具有敞开的顶表面; 形成在容器主体的后表面上以允许其打开/关闭的门; 以及用于从门的两侧表面锁定或解锁门的锁定部分。

7. 发明申请

WO2012011777A2 KIT FOR DIAGNOSING COLORECTAL CANCER AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF COLORECTAL CANCER 审中-公开
标题翻译：用于诊断颜色性癌症和药物组合物的工具包，用于预防或治疗色素性癌症
公开(公告)号：WO2012011777A2
公开(公告)日：2012-01-26
申请号：PCT/KR2011005431
申请日：2011-07-22
申请人： KOREA RES INST OF BIOSCIENCE , CHUNG KYUNG SOOK , WON MI SUN , KIM YOUNG JOO , SONG EUN YOUNG , AHN JI WON , YEOM YOUNG IL , LEE HEE GU , JANG YEO-JIN
发明人： CHUNG KYUNG SOOK , WON MI SUN , KIM YOUNG JOO , SONG EUN YOUNG , AHN JI WON , YEOM YOUNG IL , LEE HEE GU , JANG YEO-JIN
IPC分类号： C12Q1/68 , A61P35/00 , C12N15/12 , G01N33/574
CPC分类号： G01N33/57419 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention relates to: a composition for diagnosing colorectal cancer containing a formulation for measuring the expression level of a chromosome 1 open reading frame 135 (C1orf135) gene mRNA or the protein thereof; a kit for diagnosing colorectal cancer containing the composition; a method for providing information on diagnosis of colorectal cancer, the method comprising a step for measuring the expression level of a C1orf135 gene mRNA or the expression level of the protein coded by the gene; a pharmaceutical composition for the prevention or the treatment of colorectal cancer, the composition comprising an expression inhibitor for a C1orf135 gene or an activity inhibitor for the protein thereof; and a method for screening a therapeutic agent for colorectal cancer. The present invention enables the accurate diagnosis of colorectal cancer by providing a gene specific to colorectal cancer, and a diagnostic marker for determining the metastasis and prognosis of colorectal cancer, and can be useful in the diagnosis and prognosis management of colorectal cancer. Also, the present invention enables the development of new bio-medicines having fewer side effects and customized anticancer drugs by providing a colorectal cancer-specific therapeutic agent capable of inhibiting the gene.
摘要翻译：本发明涉及：用于诊断结肠直肠癌的组合物，其含有用于测量染色体1开放阅读框135（C1orf135）基因mRNA或其蛋白质的表达水平的制剂; 用于诊断含有该组合物的结肠直肠癌的试剂盒; 提供关于结肠直肠癌诊断的信息的方法，所述方法包括测定C1orf135基因mRNA的表达水平或由所述基因编码的蛋白质的表达水平的步骤。用于预防或治疗结肠直肠癌的药物组合物，所述组合物包含C1orf135基因的表达抑制剂或其蛋白质的活性抑制剂; 以及筛选结直肠癌治疗剂的方法。本发明能够通过提供对结肠直肠癌特异性的基因和用于确定结肠直肠癌的转移和预后的诊断标记物来准确诊断结肠直肠癌，并且可用于结肠直肠癌的诊断和预后管理。此外，通过提供能够抑制该基因的结肠直肠癌特异性治疗剂，本发明使得能够开发具有较少副作用的新生物药物和定制的抗癌药物。

8. 发明申请

WO2011065677A3 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER 审中-公开
标题翻译：治疗癌症的药物组合物
公开(公告)号：WO2011065677A3
公开(公告)日：2011-11-03
申请号：PCT/KR2010007600
申请日：2010-11-01
申请人： KOREA RES INST OF BIOSCIENCE , WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG JOO , HONG HYE KYUNG , YEOM YOUNG IL , YUN CHAE OK , OH YU KYUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , KIM MOON HEE , JUNG KYEONG-EUN
发明人： WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG JOO , HONG HYE KYUNG , YEOM YOUNG IL , YUN CHAE OK , OH YU KYUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , KIM MOON HEE , JUNG KYEONG-EUN
IPC分类号： A61K31/7105 , A61K31/711 , A61P35/00
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , C12N2310/531
摘要： The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
摘要翻译：本发明提供用于治疗癌症的药物组合物，其包含选自用于编码与FLJ25416基因的转录物（mRNA转录物）的碱基序列互补结合的小干扰RNA（siRNA）的脱氧核糖核酸（DNA）中的至少一种，序列号3，序列号5和序列号7以抑制FLJ25416基因的细胞内表达，抑制FLJ25416基因表达的反义RNA和抑制FLJ25416基因表达的短发夹RNA（shRNA）。由于本发明的与FLJ25416基因，反义RNA和shRNA的转录物（mRNA转录物）的碱基序列互补的siRNA抑制已知表达癌细胞，从而杀死癌细胞，本发明的组合物可以用作新型的抗癌剂。

9. 发明申请

WO2009072831A3 NOVEL USE OF FLJ25416 GENE 审中-公开
标题翻译： FLJ25416基因的新用途
公开(公告)号：WO2009072831A3
公开(公告)日：2009-08-20
申请号：PCT/KR2008007196
申请日：2008-12-05
申请人： KOREA RES INST OF BIOSCIENCE , SAMCHULLY PHARM CO LTD , WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG-JOO , CHOI SHIN-JUNG , YEOM YOUNG IL , KIM SEON-YOUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , CHUN HO KYUNG , YUN CHAE-OK , KIM MOON HEE , JUNG KYEONG-EUN , CHO SUN-JUNG
发明人： WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG-JOO , CHOI SHIN-JUNG , YEOM YOUNG IL , KIM SEON-YOUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , CHUN HO KYUNG , YUN CHAE-OK , KIM MOON HEE , JUNG KYEONG-EUN , CHO SUN-JUNG
IPC分类号： A61K38/17 , A61P35/00
CPC分类号： G01N33/57484 , A61K31/7088 , A61K38/1709 , C12N15/1135 , C12N15/86 , C12N2310/111 , C12N2310/14 , C12N2710/10343 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N2500/00 , G01N2500/04
摘要： Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.
摘要翻译：本发明提供了用于诊断癌症或筛选包含FLJ25416基因或针对由FLJ25416基因表达的蛋白质的抗体的抗癌药物的组合物，用于治疗癌症的组合物，所述组合物包含所述基因的抑制剂或由所述基因表达的蛋白质的抑制剂和药学上可接受的载体以及用于诊断癌症的试剂盒，其包含FLJ25416基因和由FLJ25416基因表达的蛋白质中的至少一种。 FLJ25416基因在特定癌细胞中高水平表达，并诱导正常细胞增殖速率增加。该基因的表达被抑制，这导致对癌细胞生长的抑制作用。因此，FLJ25416基因可以用作诊断或治疗癌症的靶基因。

10. 发明申请

WO2011149212A3 VEHICLE INTERMEDIATE SHAFT 审中-公开
标题翻译：车辆中间轴
公开(公告)号：WO2011149212A3
公开(公告)日：2012-03-01
申请号：PCT/KR2011003632
申请日：2011-05-17
申请人： KOREA DELPHI AUTOMOTIVE SYSTEM , KIM YOUNG-JOO , KIM HYON-CHUL , JUNG SE-HUN
发明人： KIM YOUNG-JOO , KIM HYON-CHUL , JUNG SE-HUN
IPC分类号： B62D1/16 , B62D1/19
CPC分类号： B62D1/16 , F16C3/035 , F16C29/046 , F16C2326/24
摘要： The present invention relates to a vehicle intermediate shaft, having a clearance reduction structure. The vehicle intermediate shaft includes: a tubular shaft which is opened at the front end thereof and formed with a hollow portion in the longitudinal direction; a solid shaft formed in the shape of a rod and inserted into the hollow portion; and a sliding member mounted between the inner surface of the tubular shaft and the outer surface of the solid shaft. The vehicle intermediate shaft further includes a preload section for pressing the outer surface of the tubular shaft. The preload section includes a pressing member for surrounding the outer surface of the tubular shaft, and a bushing for pressing and surrounding the outer surface of the pressing member. According to the present invention, it is possible to reduce clearances and lashes generated among the solid shaft, the slide member and the tubular shaft, and to prevent from creating noise. In addition, it is possible to improve the riding and handling performances of a vehicle and responsibility of a vehicle. Furthermore, production and quality control costs may be reduced by shortening process.
摘要翻译：本发明涉及具有间隙减小结构的车辆中间轴。车辆中间轴包括：管状轴，其在其前端开口并在纵向方向上形成有中空部分; 形成为杆状并插入中空部的实心轴; 以及安装在管状轴的内表面和实心轴的外表面之间的滑动构件。车辆中间轴还包括用于按压管状轴的外表面的预加载部。预压部包括用于围绕管状轴的外表面的按压部件和用于挤压和围绕按压部件的外表面的衬套。根据本发明，可以减少在实心轴，滑动构件和管状轴之间产生的间隙和睫毛，并且防止产生噪音。此外，可以提高车辆的骑行和处理性能以及车辆的责任。此外，通过缩短处理可以减少生产和质量控制成本。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式